The Research Team
Max International is committed to being the global leader in understanding how the body produces glutathione and how to develop products that enhance this process. The Max Research Team is at the forefront of this effort, and their experience sets Max apart from other companies.
Although Max was founded only in 2007, our growing expertise is based on more than 25 years of research performed by Dr. Herbert Nagasawa, who joined Max in 2009. His findings build on the research of Dr. Robert Keller that led to the development of MaxGXL®. Their work firmly establishes Max as the undisputed leader in all aspects of the glutathione industry. Max International’s science, formulations and patents will provide the public with unprecedented glutathione research and products for years to come.
Dr. Herbert T. Nagasawa, Executive Research Scientist
Dr. Nagasawa received his B.S. degree in chemistry from Western Reserve University (now, Case-Western Reserve) in Cleveland, Ohio, and a Ph.D. degree in organic chemistry from the University of Minnesota. Subsequently, he spent two years as a Post-doctoral Fellow in biochemistry at the University of Minnesota before joining the research staff of the V.A. Medical Center in Minneapolis as a Senior Chemist. He was appointed Assistant Professor of Medicinal Chemistry at the University of Minnesota in 1959. He was named Principal Scientist of the VAMC in 1961 and was promoted in 1976 to Senior Research Career Scientist, a nationwide VA title reserved for the VA’s top scientists. He was promoted to Associate Professor in 1963 and to Professor of Medicinal Chemistry in 1973. He also held joint professorships in the Department of Pharmacology and the university-wide Division of Toxicology, and served as Visiting Professor at Washington State University in 1990. He also served for 32 years as a Senior Editor for the prestigious international Journal of Medicinal Chemistry from 1972 to 2004, and one year as Acting Editor-in-Chief. In addition, he served on the Editorial Board of the journal, Bioconjugate Chemistry for eight years, and as an ad hoc grant reviewer for the NCI and NIAAA, National Institutes of Health. He has published over 165 papers in peer-reviewed journals. In June of 2010, Herb attended the National Institutes of Health-Homeland Security 4th Annual Countermeasures Against Chemical Threats Network Symposium held in San Francisco. Herb and the team of scientists presented their work on the cyanide antidote.
Scott Nagasawa, Pharm.D., Executive Director of Product Development
Scott Nagasawa received his Doctor of Pharmacy degree from the University of Southern California (USC) and is also a registered pharmacist. He spent over a dozen years at a 400-plus bed tertiary teaching hospital in Los Angeles, California, affiliated with the University of Southern California. At the time of his departure, he was the Director of Pharmaceutical Services. During this period, he held the position of Clinical Instructor of Pharmacy Practice at USC and was later promoted to Adjunct Assistant Professor of Pharmacy Practice.
Scott transitioned to the business side of his profession and joined a regional pharmacy as their Vice President of Pharmacy Services. He was instrumental in the planning and implementation of a strategic business plan transforming the company from a regional to a nationwide pharmacy service provider with revenues exceeding $60 million annually. At the time of his departure, he held the position of Senior Vice President of Professional Services responsible for nursing and pharmacy operations nationwide. He left to co-found a home infusion pharmacy and helped develop and implement a business plan that resulted in rapid growth to become a statewide provider. The company was sold in 2005. He remained with the company as V.P. of Operations and, at the time of his departure, the monthly revenue had grown by roughly 40 times. This revenue growth occurred over his four and a half years with the company.
Scott, an original co-founder of CellGevity, then left to join Dr. Herb Nagasawa and Scott Momii at CellGevity, and served full-time as the Chief Technical Officer (CTO). As CTO he was responsible for product registration, company certifications, regulatory practices, safety studies, technical sales support and the development and reviewing of product documentation.
Scott Momii, Executive Director of Product Research
Scott Momii was co-founder of a prominent research, development and manufacturing company for specialty chemicals. His management responsibilities included overseeing and implementation of sales and marketing programs, domestic and international purchasing, as well as customer service and accounting. He spearheaded the development and launch of three products in the areas of cosmetics (which debuted in Japan), the motion picture film industry, and a proprietary coating for high-speed ball bearings used in medical applications. He was responsible for transferring the manufacturing of a proprietary chemical from the U.S. to India. Simultaneously, he served as Director of Operations of a sister company developing biotechnology vaccines and cancer therapeutics, and specializing in pharmaceutical delivery systems based on liposomal technology.
Early in his career, he helped start a software company that developed a UNIX-based enterprise system designed for home infusion therapy and outpatient pharmacies. He was responsible for the sales of the software to over 200 hospitals, pharmacies and five national companies. He engineered the eventual sale of the company to the largest nationwide software provider for home healthcare solutions.
Mr. Momii graduated with a B.A. degree from San Jose State University, received an M.B.A. from Boston University, and completed a summer business program at Sophia University, Tokyo, Japan.